Biogen's Success with Leqembi Expansion and Treatment Duration
Wednesday, 24 April 2024, 16:45
Introduction
Biogen has seen significant growth with Leqembi, especially in the number of unique prescribers.
Field Force Expansion
The company is expanding its field force by 30% to further drive acceleration in large IDNs.
Treatment Duration
Physicians indicate that patients are staying on Leqembi treatment as expected, showing positive duration of treatment.
Focus on Patient Adherence
Biogen's focus remains on driving acceleration and maintaining patient adherence to improve treatment outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.